Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension rollover study of ocrelizumab in multiple sclerosis
NL-OMON55946Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ocrelizumab, sponsored by Roche. Started Nov 2022; status: recruiting.
02
Drugs
ocrelizumab
Beyond the preview
Go deeper on NL-OMON55946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55946.